| Filed On | Filing |
|---|---|
| 23 Oct 2026 | 144 |
| 23 Oct 2026 | 144 |
| 23 Oct 2026 | 144 |
| 21 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Prediction of Retinal Sensitivity Changes Following Treatment in BEST Disease George Magrath, MD Retina in Rio 2026 |
| 02 Oct 2026 |
Form 4: Foundation Fighting Blindness Retinal Degeneration Fund, Director and 1 other
Sold 556,000 shares ($2.76M) |
| 11 Sep 2026 |
Form 4: Magrath George, Director
Received 392,157 shares by exercise or conversion ($451K) · Gave up 75,541 shares to cover exercise price or tax ($451K) |
| 11 Sep 2026 |
8-K: Regulation FD Disclosure
OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 |
| 09 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month Results September 9, 2026 |
| 08 Sep 2026 |
Form 4: Gallagher Cam, Director
Received 784,314 shares by exercise or conversion ($902K) |
| 08 Sep 2026 |
Form 4: Gagnon Robert E., Chief Financial Officer
Sold 28,000 shares ($127K) |
| 03 Sep 2026 | 144 |
| 14 Aug 2026 | EFFECT |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | CORRESP |
| 12 Aug 2026 | UPLOAD |
| 07 Aug 2026 | S-3 |
| 06 Aug 2026 | 10-Q |
Loading...
